指南与共识慢病管理

基层2型糖尿病成人监测检测的循证评价:快速综述与共识

Evidence-based tests to monitor adults with type 2 diabetes mellitus in primary care: rapid reviews and consensus process.
指南 / 共识 · Br J Gen Pract · 2025-10-30

该研究通过快速综述和共识流程评估基层2型糖尿病监测检测的循证依据,发现15项检测中仅糖化血红蛋白和估算肾小球滤过率有强证据支持,多数常规检测缺乏证据,建议避免无额外临床指征的非循证检测。

要点

  • 仅糖化血红蛋白和估算肾小球滤过率有强证据支持用于2型糖尿病监测。
  • 果糖胺、甲状腺功能、维生素B12、铁蛋白、叶酸、凝血、骨代谢、C反应蛋白、血沉、B型利钠肽及肝功能(监测二甲双胍不良反应)常规检测被共识认为不必要。
  • 血脂和血红蛋白筛查继发疾病、维生素B12筛查二甲双胍不良反应的证据不足。

核心结论

  • 大多数2型糖尿病监测检测的循证依据薄弱或缺失,临床医生应避免无额外临床指征的非循证检测。

研究设计与样本

  • 研究在基层医疗环境中开展快速综述,并采用共识流程评估证据基础。

主要发现

  • 在15项检测中,仅糖化血红蛋白(监测疾病进展和治疗反应)和估算肾小球滤过率(检测慢性肾脏病)具有强证据基础。

关键数值与推荐

  • 基于现有证据和共识小组反馈,常规检测果糖胺(监测疾病进展)、甲状腺功能、维生素B12、铁蛋白、叶酸、凝血、骨代谢、C反应蛋白、血沉、B型利钠肽以及肝功能(监测二甲双胍不良反应)被认为不必要。
  • 研究认为血脂和血红蛋白用于筛查继发疾病、维生素B12用于筛查服用二甲双胍者不良反应的证据不足。

临床怎么用

  • 临床医生应避免无额外临床指征的非循证检测,标准化循证检测面板可能减少不必要的检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: When monitoring long-term conditions, both over- and undertesting can risk patient harm and increase healthcare costs. AIM: To evaluate the evidence base for type 2 diabetes mellitus (T2DM) monitoring tests and develop methods for creating evidence-based testing strategies. DESIGN AND SETTING: Rapid reviews were conducted and a consensus process then used to evaluate the evidence base within primary care settings. METHOD: The authors identified tests that are recommended or used commonly to monitor T2DM. Filtering questions were created to examine the rationale for use of each test, which were answered by stepwise rapid reviews of evidence cited by guidelines, systematic reviews, and individual studies. A consensus group of patient representatives and clinicians voted whether tests should be included or excluded based on the evidence or whether further evidence was needed. RESULTS: Of 15 tests, only haemoglobin A1c, to monitor disease progression and treatment response, and estimated glomerular filtration rate, to detect chronic kidney disease, have a strong evidence base. Based on available evidence and consensus group feedback, routinely testing for fructosamine to monitor disease progression; thyroid function, vitamin B12, ferritin, folate, clotting, bone profile, C-reactive protein, erythrocyte sedimentation rate, and B-type natriuretic peptide; and liver function for adverse treatment effects of metformin was deemed unnecessary. The study found insufficient evidence for lipids and haemoglobin to screen for secondary conditions, and for vitamin B12 to screen for adverse effects in those taking metformin. CONCLUSION: The study found that the evidence base for most T2DM monitoring tests is weak or absent. Clinicians should avoid non-evidence-based tests unless there are additional clinical indications for testing. Standardised evidence-based testing panels for T2DM and other long-term conditions could reduce unnecessary testing.

来源:Br J Gen Pract,查看原文。版权归原作者所有。

引用

  1. Elwenspoek MM, O'Donnell R, Jackson J, et al. Evidence-based tests to monitor adults with type 2 diabetes mellitus in primary care: rapid reviews and consensus process. Br J Gen Pract. 2025. PMID: 40328488. doi:10.3399/BJGP.2024.0744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。